We are live on ! Find out more
JANX icon

Janux Therapeutics

49 hedge funds and large institutions have $388M invested in Janux Therapeutics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 18 increasing their positions, 12 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 12

22% more capital invested

Capital invested by funds: $318M → $388M (+$70.1M)

11% more funds holding

Funds holding: 4449 (+5)

6.21% more ownership

Funds ownership: 69.45%75.66% (+6.2%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
49
Holders Change
+5
Holders Change %
+11.36%
% of All Funds
0.84%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
5
Increased
18
Reduced
12
Closed
Calls
$2K
Puts
Net Calls
+$2K
Net Calls Change
+$2K
Name Holding Trade Value Shares
Change
Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$117M
Fidelity Investments
2
Fidelity Investments
Massachusetts
$84.6M +$5.63M +421,688 +7%
Janus Henderson Group
3
Janus Henderson Group
United Kingdom
$53.1M +$23.9M +1,792,291 +84%
Citadel Advisors
4
Citadel Advisors
Florida
$25.1M -$2.89K -216 -0%
BI
5
BVF Inc
California
$19.9M
EC
6
EcoR1 Capital
California
$19.2M
BlackRock
7
BlackRock
New York
$16.9M +$561K +41,994 +3%
Vanguard Group
8
Vanguard Group
Pennsylvania
$10.3M +$1.48M +110,834 +17%
5VM
9
5AM Venture Management
California
$6.04M
WP
10
Woodline Partners
California
$5.42M +$1.52M +113,798 +40%
Adage Capital Partners
11
Adage Capital Partners
Massachusetts
$5.42M
SB
12
Samsara BioCapital
California
$4.88M
Geode Capital Management
13
Geode Capital Management
Massachusetts
$4.53M +$680K +50,901 +18%
State Street
14
State Street
Massachusetts
$3.58M +$2.47K +185 +0.1%
Morgan Stanley
15
Morgan Stanley
New York
$1.92M +$1.52M +113,747 +410%
Northern Trust
16
Northern Trust
Illinois
$1.85M +$42.8K +3,207 +2%
Cerity Partners
17
Cerity Partners
New York
$1.43M -$601K -45,000 -30%
JP Morgan Chase
18
JP Morgan Chase
New York
$1.42M +$21K +1,575 +2%
N
19
Nuveen
North Carolina
$987K -$26.7K -1,996 -3%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$679K +$103K +7,707 +18%
DekaBank Deutsche Girozentrale
21
DekaBank Deutsche Girozentrale
Germany
$669K
Charles Schwab
22
Charles Schwab
California
$631K +$54.2K +4,053 +10%
PL
23
Parkwood LLC
Ohio
$452K -$5.32K -398 -1%
RhumbLine Advisers
24
RhumbLine Advisers
Massachusetts
$346K +$22.4K +1,678 +7%
Bank of America
25
Bank of America
North Carolina
$206K -$138K -10,361 -41%

JANX Hedge Fund Activity: Q3 2022 in Review

49 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q3 2022, worth a combined $388M — up 22% from $318M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new JANX positions and 0 closed out — a net gain of 5 holders — while 18 added to existing stakes and 12 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $23.9M. The largest seller was Cerity Partners, cutting an estimated $601K.

  • 49 institutional investors held Janux Therapeutics (JANX) as of Q3 2022, up from 44 in Q2 2022.
  • Funds reported $388M of Janux Therapeutics stock for Q3 2022, up 22% quarter-over-quarter.
  • 5 funds opened new Janux Therapeutics positions in Q3 2022 and 0 closed out, a net change of +5 holders.
  • The largest Janux Therapeutics buyer in Q3 2022 was Janus Henderson Group, an estimated $23.9M added.
  • The largest Janux Therapeutics seller in Q3 2022 was Cerity Partners, an estimated $601K sold.

Based on aggregated 13F filings for Q3 2022.